Life360, Inc. (ASX:360): Updated its agreements with partners Arity and Placer.ai.
San Francisco based Life360, Inc. (NASDAQ:LIF) (ASX:360) has updated its agreements with partners Arity and Placer.ai. 🤝 These partnerships support Life360’s pursuit of delivering increasing value to its members 📱 Through Life360 mobile applications on iOS and Android devices, and also creating and developing new revenue streams. ASX announcement ⚡ https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02837016-2A1540150&v=fc9bdb61fe50ea61f8225e24ce041a0e155a9400
Neuren Pharmaceuticals Limited (ASX:NEU): Reports top-line results from its Phase 2 clinical trial
Neuren Pharmaceuticals Limited (ASX:NEU) has reported top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Angelman syndrome. 🩺 Clinician and caregiver global efficacy measures specifically designed for Angelman syndrome showed a level of improvement 💊 NNZ-2591 was safe and well tolerated as an oral liquid dose, with no serious adverse events […]
Codeifai (ASX: CDE): Expands reach through canva partnership
Codeifai (ASX: CDE) has reported a potentially high-value strategic integration of its QR code generation and management platform, ConnectQR, into the Canva App Marketplace. 🎨 Canva’s 180m monthly active users now have access to ConnectQR through the Canva App Marketplace 🖼️ Users can now seamlessly integrate our dynamic, static and AI QR codes 🖍️ ConnectQR […]
LTR Pharma (ASX:LTP) rallies after second medical practitioner starts prescribing SPONTAN®
LTR Pharma (ASX:LTP) rallied on news that a second medical practitioner has been authorised to prescribe SPONTAN® under the Therapeutic Goods Administration (“TGA”) Special Access Scheme (“SAS”).. A second men’s health expert and clinical key opinion leader in Australia is now authorised to prescribe SPONTAN® – a novel treatment for erectile dysfunction (“ED”) LTR Pharma […]
August 8, 2024: TSN’s ASX weekly wrap
TSN ASX weekly wrap | The ASX 200 closed on Friday evening down 2.11%. The mood in the sector took a sharp downturn after overnight data indicated a weakening US economy, reigniting concerns that persistently high interest rates could lead to a recession #ASX #ASXStocks #investment #australianstockhorse #stockshow #investing #asxweeklywrap
Nuren Group Limited (NSX:NRN): Lists on NSX
Nuren Group Limited (NSX:NRN) has listed on the National Stock Exchange of Australia with a ticker code of NRN, achieving an initial market value of $30.9 million. Nuren Group is the holding company of Enlinea who operates an e-commerce platform in Malaysia called motherhood.com.my. The platform generates revenue by purchasing products from suppliers at a […]
Gold Mountain (ASX:GMN): Achieves further exploration success
Gold Mountain (ASX:GMN) has received a batch of 54 stream sediment samples from the Irajuba tenements in the Down Under Project area in Brazil 🪨 Very high grade results in stream sediment samples demonstrate 👉 Jiquiriçá tenements in Down Under have excellent REE potential. ASX announcement: https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02836200-2A1539635&v=fc9bdb61fe50ea61f8225e24ce041a0e155a9400
What’s Hot – BPH, HCL, CTM, LBT, HCH, AW1, AWJ & PSC
What’s Hot, Not & Doing Brought to you by TSN Contributor & Wealth Advisor Nick Kelso What’s Hot – BPH, HCL, CTM, LBT, HCH, AW1, AWJ & PSC What’s Not – CAZ & MOZ What’s Hot BPH – BPH Energy Limited today closed up 38% to finish at 2.2c on $1.3m stock traded. The reason […]
Nyrada Inc. (ASX:NYR): Developing NYR-BI03
Nyrada Inc. (ASX:NYR) has made progress on developing NYR-BI03, a first in class neuroprotection treatment for both traumatic brain injury (TBI) and stroke. – Additional study provided further data to support safety and tolerability of Nyrada’s lead Brain Injury drug candidate. – Rat CNS testing satisfactorily completed under Good Laboratory Practice (GLP) conditions for NYR-BI03. […]
LTR Pharma (ASX:LTP) indicates first patients have received SPONTAN® under TGA Scheme
LTR Pharma (ASX:LTP) has announced that the first patients have received SPONTAN®, a nasal spray treatment for erectile dysfunction (ED), under the Therapeutic Goods Administration (TGA) Special Access Scheme. First patients receive SPONTAN® under the TGA Special Access Scheme Demonstrates potential for SPONTAN® in an unmet fast-acting, on-demand erectile dysfunction treatment market Internationally recognised Key […]